Armistice Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Armistice Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,200,000	Closed	-$71.5K	–	207
2022 Q2	$71.5K	Buy	10,200,000 +1,828,000	+22%	+$13.4M	1.25%	18
2022 Q1	$69.4M	Sell	8,372,000 -1,200,000	-13%	-$8.48M	1.34%	14
2021 Q4	$64.8M	Sell	9,572,000 -428,000	-4%	-$2.81M	1.06%	23
2021 Q3	$53M	Hold	10,000,000	–	–	0.9%	24
2021 Q2	$57.5M	Hold	10,000,000	–	–	1.03%	24
2021 Q1	$46.1M	Hold	10,000,000	–	–	1.06%	30
2020 Q4	$33.4M	Hold	10,000,000	–	–	1.14%	26
2020 Q3	$29.7M	Buy	10,000,000 +3,800,000	+61%	+$14.9M	1.08%	34
2020 Q2	$28.6M	Buy	6,200,000 +800,000	+15%	+$3.59M	1.26%	28
2020 Q1	$20.8M	Buy	5,400,000 +300,000	+6%	+$1.23M	1.29%	33
2019 Q4	$19.1M	Buy	+5,100,000	New	+$23.8M	1.1%	31
2019 Q3	–	Sell	-5,000,000	Closed	-$19.2M	–	70
2019 Q2	$19.2M	Buy	5,000,000 +3,480,000	+229%	+$15M	1.21%	29
2019 Q1	$7.75M	Buy	1,520,000 +140,000	+10%	+$412K	0.42%	44
2018 Q4	$2.65M	Sell	1,380,000 -292,000	-17%	-$836K	0.2%	54
2018 Q3	$6.32M	Sell	1,672,000 -28,000	-2%	-$87.7K	0.38%	54
2018 Q2	$5.3M	Buy	+1,700,000	New	+$5.16M	0.35%	60

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital's CPRX Position: Q3 2022 in Review

Armistice Capital sold out of Catalyst Pharmaceutical (CPRX) in Q3 2022, closing a stake of 10,200,000 shares — an estimated $71.5K sold.

Armistice Capital first reported a position in CPRX in Q2 2018 and held it in 16 quarters. The position peaked at $69.4M in Q1 2022. 229 funds tracked by Wall St. Rank hold CPRX as of Q3 2022.

Armistice Capital reported no remaining Catalyst Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Armistice Capital sold 10,200,000 Catalyst Pharmaceutical shares in Q3 2022, an estimated $71.5K.
Armistice Capital first reported a position in Catalyst Pharmaceutical in Q2 2018 and held it in 16 quarters.
Armistice Capital's Catalyst Pharmaceutical position peaked at $69.4M in Q1 2022.
229 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2022.

Based on Armistice Capital's 13F filing for Q3 2022, filed 14 Nov 2022.